Global GLP-1 Agonist Market 2023 by Manufacturers, Regions, Type and Application, Forecast to 2029

Global GLP-1 Agonist Market 2023 by Manufacturers, Regions, Type and Application, Forecast to 2029

According to our (Global Info Research) latest study, the global GLP-1 Agonist market size was valued at USD 21200 million in 2022 and is forecast to a readjusted size of USD 59500 million by 2029 with a CAGR of 15.9% during review period. The influence of COVID-19 and the Russia-Ukraine War were considered while estimating market sizes.

GLP-1 is a polypeptide hormone secreted by the intestine after being stimulated by food. It can stimulate the pancreatic beta cells to secrete insulin and participate in the regulation of blood sugar balance in the human body. However, natural GLP-1 is easily degraded by dipeptidyl peptidase in vivo and loses its activity. In order to make GLP-1 better for clinical application, drug developers have modified its structure and developed a series of GLP-1 receptor agonists. GLP-1 receptor agonists can exert the same biological effects as natural GLP-1, and can also avoid being degraded and inactivated, thereby prolonging the action time.

This report is a detailed and comprehensive analysis for global GLP-1 Agonist market. Both quantitative and qualitative analyses are presented by manufacturers, by region & country, by Type and by Application. As the market is constantly changing, this report explores the competition, supply and demand trends, as well as key factors that contribute to its changing demands across many markets. Company profiles and product examples of selected competitors, along with market share estimates of some of the selected leaders for the year 2023, are provided.

Key Features:

Global GLP-1 Agonist market size and forecasts, in consumption value ($ Million), sales quantity (K Units), and average selling prices (US$/Unit), 2018-2029

Global GLP-1 Agonist market size and forecasts by region and country, in consumption value ($ Million), sales quantity (K Units), and average selling prices (US$/Unit), 2018-2029

Global GLP-1 Agonist market size and forecasts, by Type and by Application, in consumption value ($ Million), sales quantity (K Units), and average selling prices (US$/Unit), 2018-2029

Global GLP-1 Agonist market shares of main players, shipments in revenue ($ Million), sales quantity (K Units), and ASP (US$/Unit), 2018-2023

The Primary Objectives in This Report Are:

To determine the size of the total market opportunity of global and key countries

To assess the growth potential for GLP-1 Agonist

To forecast future growth in each product and end-use market

To assess competitive factors affecting the marketplace

This report profiles key players in the global GLP-1 Agonist market based on the following parameters - company overview, production, value, price, gross margin, product portfolio, geographical presence, and key developments. Key companies covered as a part of this study include Novo Nordisk, AstraZeneca, Sanofi, GSK and Eli Lilly, etc.

This report also provides key insights about market drivers, restraints, opportunities, new product launches or approvals, COVID-19 and Russia-Ukraine War Influence.

Market Segmentation

GLP-1 Agonist market is split by Type and by Application. For the period 2018-2029, the growth among segments provides accurate calculations and forecasts for consumption value by Type, and by Application in terms of volume and value. This analysis can help you expand your business by targeting qualified niche markets.

Market segment by Type
Long-Acting Drug
Short-Acting Drug

Market segment by Application
Diabetes
Obesity
Nonalcoholic Fatty Liver Disease
Metabolic Disorder
Alzheimer's Disease
Other

Major players covered
Novo Nordisk
AstraZeneca
Sanofi
GSK
Eli Lilly
Zealand Pharma A/S
hansoh
BENEMAE

Market segment by region, regional analysis covers
North America (United States, Canada and Mexico)
Europe (Germany, France, United Kingdom, Russia, Italy, and Rest of Europe)
Asia-Pacific (China, Japan, Korea, India, Southeast Asia, and Australia)
South America (Brazil, Argentina, Colombia, and Rest of South America)
Middle East & Africa (Saudi Arabia, UAE, Egypt, South Africa, and Rest of Middle East & Africa)

The content of the study subjects, includes a total of 15 chapters:

Chapter 1, to describe GLP-1 Agonist product scope, market overview, market estimation caveats and base year.

Chapter 2, to profile the top manufacturers of GLP-1 Agonist, with price, sales, revenue and global market share of GLP-1 Agonist from 2018 to 2023.

Chapter 3, the GLP-1 Agonist competitive situation, sales quantity, revenue and global market share of top manufacturers are analyzed emphatically by landscape contrast.

Chapter 4, the GLP-1 Agonist breakdown data are shown at the regional level, to show the sales quantity, consumption value and growth by regions, from 2018 to 2029.

Chapter 5 and 6, to segment the sales by Type and application, with sales market share and growth rate by type, application, from 2018 to 2029.

Chapter 7, 8, 9, 10 and 11, to break the sales data at the country level, with sales quantity, consumption value and market share for key countries in the world, from 2017 to 2022.and GLP-1 Agonist market forecast, by regions, type and application, with sales and revenue, from 2024 to 2029.

Chapter 12, market dynamics, drivers, restraints, trends, Porters Five Forces analysis, and Influence of COVID-19 and Russia-Ukraine War.

Chapter 13, the key raw materials and key suppliers, and industry chain of GLP-1 Agonist.

Chapter 14 and 15, to describe GLP-1 Agonist sales channel, distributors, customers, research findings and conclusion.